GlassScriptPhysician profile
Brittany E Herrin
NPI 1124548102
$7,617.75
in general payments reported to CMS, 2019-2025
37 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $215 · 2021: $411 · 2022: $1,269 · 2023: $1,792 · 2024: $1,542 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,011 · Education: $77.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,011.42 |
| Education | $77.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,228.29 | 2021-2025 | |
| Amgen INC. | $1,052.90 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $886.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $365.92 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $328.37 | 2019-2025 | Ozempic |
| Pfizer INC. | $232.68 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.99 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $176.79 | 2019-2022 | |
| Medtronic, INC. | $157.69 | 2022 | |
| Sumitomo Pharma America, INC. | $138.49 | 2023-2025 | Gemtesa |
| Neurocrine Biosciences, INC. | $134.53 | 2024 | Ingrezza |
| Nevro Corp. | $127.05 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $125.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.79 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $119.31 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $118.41 | 2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $117.91 | 2025 | Rexulti |
| Abbott Laboratories | $114.64 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.85 | 2025 | Jardiance |
| Alkermes, INC. | $108.80 | 2023 | Lybalvi |
| Phathom Pharmaceuticals, INC. | $103.61 | 2024 | Voquezna |
| Lundbeck LLC | $97.29 | 2025 | Rexulti |
| Stryker Corporation | $94.23 | 2025 | Blueprint Patient Specific Instrumentation |
| Biohaven Pharmaceuticals, INC. | $79.24 | 2020-2021 | |
| Exact Sciences Corporation | $33.66 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $31.35 | 2019-2021 | |
| Convatec INC. | $22.57 | 2019 | |
| Viatris Specialty LLC | $21.88 | 2025 | Yupelri |
| Rhodes Pharmaceuticals L.P. | $19.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.71 | 2019 | |
| Neurelis, INC. | $15.22 | 2023 | Valtoco |
| Dexcom, INC. | $15.07 | 2024 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $13.79 | 2023 | Slynd |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2025 | Zoryve |
| Valinor Pharma, LLC | $13.47 | 2024 | Movantik |
| Organon LLC | $10.05 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Herrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.